PULM Pulmatrix, Inc.
Listings ·
Pulmatrix stockholders approved all nine proposals on October 26, 2026, including a share issue above 20% to Eos holders, certain noteholders and adviser Palladium, and a reverse split of one new share for every 2 to 10. The 8-K says Eos and Pulmatrix holders could end up owning more or less of the combined company if the exchange ratio is adjusted.
Pulmatrix stockholders are due to vote October 26, 2026 on a merger with Eos SENOLYTIX, Inc., whose lead data so far are mouse studies. The filing gives no amount for the merger-associated financings it expects, and the company's cash was $2.2 million at June 30, 2026.
Pulmatrix said the SEC declared effective the registration statement for its proposed merger with Cullgen, which it expects to close in June 2025. It plans to divest PUR3100 and its other assets as part of the deal. Its cash was $7.7 million on March 31, 2025.
Pulmatrix says the SEC has declared effective its Form S-4 for the Cullgen merger, and expects a June 2025 close while it seeks buyers for its own assets. It had $7.7 million of cash at March 31, 2025, which it says lasts through the anticipated closing.
Amendment No. 1, dated April 7, 2025, drops the second merger so Cullgen survives the merger as a wholly owned Pulmatrix subsidiary. It also clarifies the fractional shares provision.
Pulmatrix and Cullgen signed Amendment No. 1 to their merger agreement on April 7, 2025, dropping the planned second merger. The 8-K gives no exchange ratio, share count or valuation, and does not say why the structure changed.
| Line | FY2025 | FY2024 |
|---|---|---|
| Research and development | $38,000 | $7.2 million |
| Net income (loss) | -$5.2 million | -$9.6 million |
| Cash from operations | -$5.4 million | -$10.7 million |
| Cash and equivalents | $4.1 million | $9.5 million |
Our latest story on this, dated Oct 27, 2026: "Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 27, 2026: "Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split". The story links the filing or release it is based on. Read the story.
Pulmatrix, Inc. trades under the ticker PULM on NASDAQ.
Pulmatrix, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:2PU.
The SEC Central Index Key (CIK) for Pulmatrix, Inc. is 1574235. Its filings are on SEC EDGAR.
3,652,285 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-13.
Our directory records Pulmatrix, Inc. under United States.
Our directory classifies Pulmatrix, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Pulmatrix, Inc. is US74584P3010.
aibio.space lists Pulmatrix, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Pulmatrix, Inc. reported a net loss of $5.2 million for the fiscal year ended Dec 31, 2025, and used $5.4 million of cash in operations, per its annual report to the SEC.
$38,000 in the fiscal year ended Dec 31, 2025, per its annual report.
$2.2 million in cash at Jun 30, 2026, per its 10-Q.
Our latest story on Pulmatrix, dated Oct 27, 2026: "Pulmatrix stockholders approve Eos SENOLYTIX merger and a reverse split". Pulmatrix stockholders approved all nine proposals on October 26, 2026, including a share issue above 20% to Eos holders, certain noteholders and adviser Palladium, and a reverse split of one new share for every 2 to 10. The 8-K says Eos and Pulmatrix holders could end up owning more or less of the combined company if the exchange ratio is adjusted. Source.
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Filed documents for a merger or acquisition. SEC Form 425. Source
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a reverse stock split. SEC Form 8-K (Items 1.01,3.02,3.03,5.01,5.03,7.01,9.01). Source
Reported the end of a material agreement. SEC Form 8-K (Items 1.02,7.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 7.01,8.01,9.01). Source
Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01). Source
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,9.01). Source
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,5.01,5.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio